Patients with advanced solid tumors are needed for a study to research the combination of an investigational drug and chemotherapy.

UVA Tracking #
HSR200422
Principal Investigator
Linda R Duska
Contact
Anne Gabel
Contact Email
Contact Phone
434.982.6657
Official Trial Title
A phase 1/2 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AO-176
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, have stomach, endometrial, or ovarian cancer. The purpose of this study is to evaluate an experimental drug (AO-176) in combination with a chemotherapy drug (paclitaxel) in patients with stomach, endometrial, or ovarian cancer. The safety and effects of the experimental and chemotherapy drugs, along with the experimental drug dose will be evaluated for this study.
Participation includes a screening visit, drug treatment, and follow-up visits via a clinic visit or a phone call to keep track of how you are doing. You may receive drug as long as it continues to treat your disease. Study specific tests will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03834948

Compensation

You will receive up to $50 per study visit. You will receive up to $175 per night for hotel stays.